The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Global mapping of pharmacological space
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
Self-citationLigand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
Self-citationKnowledge Discovery in Databases
Piateski, G., & Frawley, W. (1991) · The MIT Press eBooks · Cited by 1,749
Simple Selection Criteria for Drug-like Chemical Matter
Muegge, I., Heald, S. L., & Brittelli, D. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm015507e · Cited by 1,315
Database Systems: A Practical Approach to Design, Implementation and Management
Connolly, T. M., & Begg, C. E. (1998) · Cited by 1,243
An Information-Intensive Approach to the Molecular Pharmacology of Cancer
Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L. V., Anderson, N. L., et al. (1997) · Science · doi:10.1126/science.275.5298.343 · Cited by 1,183
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Knowledge discovery in databases
FrawleyWilliam, J., Piatetsky-ShapiroGregory, & MatheusChristopher, J. (1992) · AI Magazine · doi:10.5555/140629.140633 · Cited by 1,055
Navigating chemical space for biology and medicine
Lipinski, C., & Hopkins, A. (2004) · Nature · doi:10.1038/nature03193 · Cited by 1,002
Self-citationThe maximal affinity of ligands
Kuntz, I. D., Chen, K., Sharp, K. A., & Kollman, P. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.9997 · Cited by 849
Handbook of Data Mining and Knowledge Discovery
Klösgen, W., & Żytkow, J. M. (2002) · Cited by 666
A Specific Mechanism of Nonspecific Inhibition
McGovern, S. L., Helfand, B. T., Feng, B., & Shoichet, B. K. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030266r · Cited by 598
A Comparison of Physiochemical Property Profiles of Development and Marketed Oral Drugs
Wenlock, M. C., Austin, R. P., Barton, P., Davis, A. M., & Leeson, P. D. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm021053p · Cited by 546
Functional group contributions to drug-receptor interactions
Andrews, P. R., Craik, D. J., & Martin, J. L. (1984) · Journal of Medicinal Chemistry · doi:10.1021/jm00378a021 · Cited by 535
Can We Learn To Distinguish between “Drug-like” and “Nondrug-like” Molecules?
Ajay, Walters, W. P., & Murcko, M. A. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970666c · Cited by 484
Walters, W. P., & Murcko, M. A. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00003-0 · Cited by 439
Chemical genetics: ligand-based discovery of gene function
Stockwell, B. R. (2000) · Nature Reviews Genetics · doi:10.1038/35038557 · Cited by 421
Selection criteria for drug‐like compounds
Muegge, I. (2003) · Medicinal Research Reviews · doi:10.1002/med.10041 · Cited by 412
Handbook of data mining and knowledge discovery
(2003) · Computers & Mathematics with Applications · doi:10.1016/s0898-1221(03)90175-1 · Cited by 390
Characteristic Physical Properties and Structural Fragments of Marketed Oral Drugs
Vieth, M., Siegel, M. G., Higgs, R. E., Watson, I. A., Robertson, D. H., Savin, K. A., Durst, G. L., & Hipskind, P. A. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030267j · Cited by 359
The Multiplicity of Serotonin Receptors: Uselessly Diverse Molecules or an Embarrassment of Riches?
Roth, B. L., Lopez, E., Patel, S., & Kroeze, W. K. (2000) · The Neuroscientist · doi:10.1177/107385840000600408 · Cited by 358
Classification of Kinase Inhibitors Using a Bayesian Model
Xia, X., Maliski, E. G., Gallant, P., & Rogers, D. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0303195 · Cited by 352
NIH Molecular Libraries Initiative
Austin, C. P., Brady, L. S., Insel, T. R., & Collins, F. S. (2004) · Science · doi:10.1126/science.1105511 · Cited by 348
Frantz, S. (2005) · Nature · doi:10.1038/437942a · Cited by 322
Rogers, D., Brown, R. D., & Hahn, M. (2005) · SLAS Discovery · doi:10.1177/1087057105281365 · Cited by 296
Recognizing molecules with drug-like properties
Walters, W. P., Murcko, A. A., & Murcko, M. A. (1999) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(99)80058-1 · Cited by 266
From Knowing to Controlling: A Path from Genomics to Drugs Using Small Molecule Probes
Strausberg, R. L., & Schreiber, S. L. (2003) · Science · doi:10.1126/science.1083395 · Cited by 260
Drugs, leads, and drug-likeness: an analysis of some recently launched drugs
Proudfoot, J. R. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00244-5 · Cited by 252
Genomic sciences and the medicine of tomorrow
Drews, J. (1996) · Nature Biotechnology · doi:10.1038/nbt1196-1516 · Cited by 246
Selective Optimization of Side Activities: Another Way for Drug Discovery
Wermuth, C. G. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030480f · Cited by 201
Drug Development: The role of innovation in drug development
Drews, J., & Ryser, S. (1997) · Nature Biotechnology · doi:10.1038/nbt1297-1318 · Cited by 178
Predicting ADME properties and side effects: the BioPrint approach.
Krejsa, C. M., Horvath, D., Rogalski, S. L., Penzotti, J. E., Mao, B., Barbosa, F., & Migeon, J. (2003) · PubMed · Cited by 176
Kinomics—structural biology and chemogenomics of kinase inhibitors and targets
Vieth, M., Higgs, R. E., Robertson, D. H., Shapiro, M., Gragg, E. A., & Hemmerle, H. (2004) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2003.11.028 · Cited by 175
Kinomics: characterizing the therapeutically validated kinase space
Vieth, M., Sutherland, J. J., Robertson, D. H., & Campbell, R. M. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03477-x · Cited by 157
Drug prototypes and their exploitation
(1997) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(97)84366-8 · Cited by 147
Molecular properties that influence oral drug-like behavior.
Lajiness, M. S., Vieth, M., & Erickson, J. A. (2004) · PubMed · Cited by 102
Biological mechanism profiling using an annotated compound library
Root, D. E., Flaherty, S. P., Kelley, B. P., & Stockwell, B. R. (2003) · Chemistry & Biology · doi:10.1016/j.chembiol.2003.08.009 · Cited by 95
Schuffenhauer, A., Zimmermann, J., Stoop, R., van der Vyver, J.-J., Lecchini, S., & Jacoby, E. (2002) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci010385k · Cited by 94
Feldman, H. J., Dumontier, M., Ling, S., Haider, N., & Hogue, C. W. V. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.07.039 · Cited by 85
Horvath, D., & Jeandenans, C. (2003) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci025634z · Cited by 83
Drug prototypes and their exploitation
(1997) · General Pharmacology The Vascular System · doi:10.1016/s0306-3623(97)90084-7 · Cited by 78
Guiding molecules towards drug-likeness.
Egan, W. J., Walters, W. P., & Murcko, M. A. (2002) · PubMed · Cited by 56
Wang, J., & Ramnarayan, K. (1999) · Journal of Combinatorial Chemistry · doi:10.1021/cc990032m · Cited by 55
Examination of the Computed Molecular Properties of Compounds Selected for Clinical Development
Blake, J. F. (2003) · BioTechniques · doi:10.2144/blakejun03 · Cited by 38
Drews, J., & Ryser, S. (1997) · Nature Biotechnology · doi:10.1038/nbt1297-1350 · Cited by 29
Annotating and mining the ligand-target chemogenomics knowledge space
Schuffenhauer, A., & Jacoby, E. (2004) · Drug Discovery Today BIOSILICO · doi:10.1016/s1741-8364(04)02408-4 · Cited by 25
Prioritizing the human genome: knowledge management for drug discovery.
Golden, J. B. (2003) · PubMed · Cited by 20
Thirty‐three years of drug discovery and research with Dr. Paul Janssen
van Gestel, S., & Schuermans, V. (1986) · Drug Development Research · doi:10.1002/ddr.430080103 · Cited by 19
Cited by
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Self-citationChEMBL: a large-scale bioactivity database for drug discovery
Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr777 · Cited by 4,382
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Self-citationA comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Metadata
- Authors
- Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., Mason, J. S., & Hopkins, A. L.
- Venue
- Nature Biotechnology
- Published
- 2006-07-01
- Volume
- 24
- Issue
- 7
- Pages
- 805-815
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W1972821149
- Cited by
- 811
- References
- 53
- FWCI
- 52.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.